anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The incidence and risk of postoperative myocardial injury in patients with coronary artery disease is high, and there is no definitive monitoring tool to predict postoperative myocardial injury. Speckle tracking imaging (STI), which quantifies strain and ventricular torsion in all segments of the heart, is more sensitive to subtle changes in myocardial contractility than conventional ultrasound. This project proposes to use 4D-STI as a means of monitoring myocardial exercise function during anaesthesia in patients with coronary artery disease, to explore the association with the occurrence of postoperative myocardial injury, and to perform a predictive study of postoperative myocardial injury. The study was designed according to a prospective follow-up cohort. The protocol was developed with reference to the STROBE guidelines for cohort studies. In this study, 2.5 ml of venous blood specimens were collected before surgery and at the end of surgery and sent to the laboratory. Intraoperative data collection was performed in the operating theatre and follow-up was obtained on the ward and during telephone follow-up.
This study was designed as a randomized, open-label, single-center, crossover study to evaluate the effect of food on the pharmacokinetics of extended-release (ER) OROS paliperidone in healthy Japanese adults. Of the 20 Japanese volunteers who are to be enrolled, at least 6 are to be men and 6 are to be women. All volunteers will receive single doses of 3 mg ER OROS paliperidone with and without a standard Japanese breakfast. There will be a 1-week washout between treatments, for a total treatment duration of approximately 2 weeks. Volunteers are to be randomly assigned to 1 of 2 treatment sequence groups (fed and fasted; fasted and fed). The pharmacokinetics of paliperidone will be assessed for 96 hours after each dosing. Safety and tolerability will be monitored throughout the study. Prior to initiating clinical trials in Japan, a food effect study is required to evaluate the effect of food on the pharmacokinetics of ER OROS paliperidone in Japanese adults.

3 mg tablets, single oral dose, once under fasting and once under fed conditions
1522182 Calcium phosphate ceramics STERLING DRUG Inc 22 July 1975 [2 Aug 1974 7 July 1975] 30706/75 Heading C1A A polycrystalline, sintered ceramic for use as a bone or tooth substitute is made by reacting calcium ion with phosphate ions in aqueous medium at pH of 10-12 to produce a gelatinous calcium phosphate precipitate having a Ca:P molar ratio of 1À44-1À72, separating the precipitate from the solution and heating the precipitate to above 1000C but below the temperature at which appreciable decomposition of hydroxylapatite occurs and maintaining said temperature for a sufficient time to effect sintering and maximum densification. When the Ca:P molar ratio is in the range 1À62-1À72 a translucent, isotropic, polycrystalline hydroxylapatite having an average crystalite size of 0À2-3 microns, a density of 3À1-3À14 g/cm<SP>3</SP>, substantially no pores and having cleavage along smooth curved planes is obtained. When the Ca:P ratio is in the range 1À44-1À60, preferably 1À46-1À57 a dense isotropic two-phase ceramic is obtained comprising 14-98% hydroxylapatite and 2-86% whitlockite, said ceramic having substantially no pores and having cleavage along smooth curved planes. The reactants are preferably Ca(NO 3 ) 2  and (NH 4 ) 2 HPO 4 . 0À4-0À6% of an organic binder, e.g. collagen, may be added to the precipitate to prevent cracking during drying. Porous forms of the ceramic may be made by including 5-25% by weight of organic binders such as powdered cellulose, starch, cotton or collagen to the precipitate. Fluoride ions may be introduced into the ceramic, e.g. by standing in 0À5-5% aqueous NaF for 12 hours-5 days.
Single dose of 1950 mg (3 tablets of 650 mg) was administered orally 2 hours before the surgical incision. The dose was administered by the nurse on duty who provided 100ml of water to swallow the pills.
PURPOSE: A use of COMT inhibitors, especially nitecapone (3-3,4-dihydroxy-5-nitrophenyl)methylene-2,4-pentanedione) in the prevention of diabetic vascular dysfunctions, such as nephropathy, retinopathy and neuropathy. CONSTITUTION: An effective dose of the compound varies considerably depending on the efficacy of the COMT-inhibitor in question, the severity of the condition to be treated, and the route of administration. Most preferred are oral formulations. The effective dose for human beings is likely to be from about 20 to 2000 mg per day. This compounds are given to a patient as such or in combination with one or more other active ingredients and/or suitable pharmaceutical non-active additives. The latter group comprises solvents, gel forming agents, emulsifiers, stabilizers, colorants, preservatives, lubricants, glidants, fillers and other widely used excipients and formulation aids.
Chronic pain and mental health issues occur at higher rates in Veterans than the general population. One widely recognized mental health issue faced by Veterans is post-traumatic stress disorder (PTSD). Trauma symptoms and pain frequently co-occur and are mutually maintained due to shared mechanisms. Many Veterans are also parents. Parental physical and mental health issues significantly predict children's chronic pain and related functioning, which can continue into adulthood. Only 1 U.S.-based study has examined pain in the offspring of Veterans, suggesting a heightened risk for pain. Research to date has not examined the associations between trauma and pain and the dyadic influences of these symptoms, among Veterans, and their children. The current study aimed to describe pain characteristics in Canadian Armed Forces Members/Veterans with chronic pain and their offspring (youth and adult children aged 9-38). Cross-lagged panel models were conducted to examine dyadic relationships between pain interference and trauma symptoms of Canadian Armed Forces Members/Veterans and their offspring. Over half of adult offspring and over one-quarter of youth offspring reported chronic pain. Results revealed effects between one's own symptoms of PTSD and pain interference. No significant effects of parents on offspring or offspring on parents were found. The findings highlight the interconnection between pain and PTSD consistent with mutual maintenance models and a lack of significant interpersonal findings suggestive of resiliency in this unique population. PERSPECTIVE: We characterized chronic pain in the offspring of Canadian Armed Forces Members/Veterans with chronic pain and examined dyadic relationships between PTSD symptoms and chronic pain interference. Findings revealed that PTSD symptoms and pain interference were related within Veterans and offspring, but no dyadic relationships were found, which could reflect resiliency.
The invention relates to a Chinese herbal medicine used for curing livestock foot and mouth diseases. The Chinese herbal medicine comprises the following Chinese herbal medicaments by weight part: 90 to 130 parts of rose moss, 90 to 130 parts of houttuynia, 90 to 130 parts of radix isatidis, 90 to 130 parts of andrographis paniculata, 90 to 130 parts of baikal skullcap root, 90 to 130 parts of forsythia, 90 to 130 parts of honeysuckle, 90 to 130 parts of hyacinth bletilla, and 90 to 130 parts of sophora flavescens ait. The Chinese herbal medicine is capable of antibiosis and antivirus, and curing local ulceration and pathological changes, which is both capable of detoxication, reducing fever, and antiinflammation, and capable of eliminating symptoms throughout the bodies caused by foot-and-mouth disease virus. The Chinese herbal medicine has remarkable curative effect on foot and mouth diseases of livestock, and has comprehensive curative effect in relieving the primary and secondary symptoms at the same time. Compared with the prior art, the Chinese herbal medicine can reduce the period of treatment by 2/3, and prevent complications with high cure rate of more than 99 percent and low mortality. By applying or spraying the Chinese herbal medicine on livestock which is not infected, or soaking the liverstock which is not infected in the Chinese herbal medicine, the Chinese herbal medicine plays a good role in preventing foot and mouth diseases.
Pregnancy Category C

There are no adequate and well-controlled studies of terbutaline sulfate in pregnant women. Published animal studies show that rat offspring exhibit alterations in behavior and brain development, including decreased cellular proliferation and differentiation when dams were treated subcutaneously with terbutaline during the late stage of pregnancy and lactation period. Terbutaline exposures in rat dams were approximately 24 to 48 times the common human dose in adults of 2-4 mg/day, on a mg/m2 basis.

Terbutaline sulfate has not been approved and should not be used for prolonged tocolysis (beyond 48-72 hours). In particular, terbutaline sulfate should not be used for maintenance tocolysis in the outpatient or home setting. Serious adverse reactions, including death, have been reported after administration of terbutaline sulfate to pregnant women. In the mother, these adverse reactions include increased heart rate, transient hyperglycemia, hypokalemia, cardiac arrhythmias, pulmonary edema and myocardial ischemia. Increased fetal heart rate and neonatal hypoglycemia may occur as a result of maternal administration (see BOXED WARNING: Prolonged Tocolysis and CONTRAINDICATIONS: Prolonged Tocolysis).

In animal embryofetal developmental studies, no teratogenic effects were observed in offspring when pregnant rats and rabbits received terbutaline sulfate at oral doses up to 50 mg/kg/day, approximately 810 and 1,600 times, respectively, the maximum recommended daily subcutaneous dose for adults, on a mg/m2 basis.

Terbutaline sulfate should be used during pregnancy only if the potential benefits justify the potential risk to the fetus.
The goal intrapartum glucose target range will be 70-160mg/dl. Insulin infusion will be initiated when maternal capillary glucose exceeds 160 mg/dL.
BACKGROUND: Approximately 30% of post-operative breast cancer patients develop shoulder joint movement disorders affecting routine upper limb movement. This study discusses the impact of a neuromuscular joint facilitation (NJF) method on the physical function of breast cancer patients experiencing shoulder dysfunction during chemotherapy after radical surgery.
METHODS: This study included 162 female patients who have unilateral breast cancer in a cancer hospital in China. They developed shoulder joint mobility disorders during chemotherapy within 1-3 months postoperatively. These patients were divided into three groups: NJF, conventional rehabilitation (conventional group), and control groups. The clinical examination included the maximum passive and active range of motion (ROM) of the shoulder (flexion, extension, abduction, adduction, and external and internal rotation). Other evaluations included a pain score using a visual analog scale (VAS), grip strength, and supraspinatus muscle thickness. All tests were evaluated pre-and post-intervention.
RESULTS: The NJF group showed a significant increase in all shoulder ROM angles post-intervention. In the conventional group, all other ROM values increased significantly, except passive external rotation ROM. In the control group, all other ROM values increased significantly, except passive and active external rotation ROM. All three groups had decreased VAS scores, increased grip strength, and supraspinatus muscle thickness post-intervention during active abduction. In the control group, the supraspinatus contraction rate decreased significantly at 60° and 90° abduction post-intervention compared to that at pre-intervention.
CONCLUSION: This study revealed that NJF during chemotherapy had positive clinical intervention effects, improving shoulder joint mobility disorders, pain, grip strength, and external rotation following radical breast cancer surgery.
CLINICAL TRIAL REGISTRATION: Chinese Clinical Trial Registry; https://www.chictr.org.cn/ (ChiCTR2300073170), registered (03/07/2023).
OBJECTIVES: We aimed to determine whether hand OA is characterized by systemic cartilage loss by assessing if radiographically normal joints had greater joint space width (JSW) loss over 4 years in hands with incident or prevalent OA elsewhere in the hand compared with hands without OA.
METHODS: We used semi-automated software to measure JSW in the distal and proximal IP joints of 3368 participants in the Osteoarthritis Initiative who had baseline and 48-month hand radiographs. A reader scored 16 hand joints (including the thumb base) for Kellgren-Lawrence (KL) grade. A joint had OA if scored as KL ≥2. We identified three groups based on longitudinal hand OA status: no hand OA (KL <2 in all 16 joints) at the baseline and 48-month visits, incident hand OA (KL <2 in all 16 joints at baseline and then one or more joints with KL ≥2 at 48 months) and prevalent hand OA (one or more joints with KL ≥2 at baseline and 48 months). We then assessed if JSW in radiographically normal joints (KL 0) differed across these three groups. We calculated unpooled effect sizes to help interpret the differences between groups.
RESULTS: We observed small differences in JSW loss that are unlikely to be clinically important in radiographically normal joints between those without hand OA (n = 1054) and those with incident (n = 102) or prevalent hand OA (n = 2212) (effect size range -0.01-0.24). These findings were robust when examining JSW loss dichotomized based on meaningful change and in other secondary analyses.
CONCLUSIONS: Hand OA is not a systemic disease of cartilage.
Participants who receive the Contingency Management (CM) intervention for 4 weeks in addition to 6 weeks of NRT. These participants are responders (have quit smoking at the 1 month follow up) or non-responders (those who have not quit smoking at the 1 month follow up) and randomized to receive no additional intervention.
To provide a medical appliance and implantation method, the medical appliance being capable of further suppressing a temperature rise of an organ at the time of implanting the organ to a recipient and hardly disturbing work of an operating surgeon.SOLUTION: This organ housing bag 1 comprises a bag-like thermal insulation sheet 10 for holding an organ 9. The thermal insulation sheet 10 includes a pair of water resistant layers and a thermal insulation layer positioned between the pair of water resistant layers. In performing an implantation operation of the organ 9, the organ 9 is disposed into a recipient's body cavity in a state in which the organ is housed in the organ housing bag 1. Thereby, anastomosis of a blood vessel is enabled while inhibiting a temperature of the organ 9 from being raised by the recipient's body temperature and an ambient temperature. As a result, occurrence of disorder after the operation can be suppressed by inhibiting the organ 9 from becoming in a warm ischemia state. In addition, because the thermal insulation sheet is formed in a bag shape, an end of the thermal insulation sheet hardly disturbs work of an operating surgeon.SELECTED DRAWING: Figure 1
PROBLEM TO BE SOLVED: To obtain modifying powder exhibiting high ability for inhibiting skin color to change into subfusc by surface treating with safflower red pigment and gardenia seeds pigment to the same powder and obtaining cosmetics using the same. SOLUTION: (A) Safflower red pigment and (B) gardenia seeds pigment are each treated on the same surface of the powder (C) (e.g.; crystalline cellulose powder). The modifying powder is preferably manufactured in the following processes. The extract solution of gardenia seeds pigment is obtained by selecting fruits of gardenia, crushing, immersing, boiling and filtering. Charging component (C) into the extract solution and dying the component (C) with component (B), filtering, drying and crushing to obtain the gardenia pigment powder. On the other hand, the safflower red pigment is prepared by selecting the flower petals of the safflower washing, filtering, immersing in an alkaline solution and filtering. The gardenia pigment powder is charged into the extract, adjusting the pH to acidic, dying the component (A), filtering, washing, drying and crushing.
The tablets contain pregelatinized corn starch, crospovidone, povidone, magnesium stearate, colloidal silicon dioxide, and stearic acid. 

Oxycodone and Acetaminophen Tablets, USP contain oxycodone, 14-hydroxy-dihydrocodeinone, a semisynthetic opioid analgesic which occurs as a white to off-white fine crystalline powder. The molecular formula for oxycodone hydrochloride is C 18H 21NO 4∙HCl and the molecular weight is 351.82. It is derived from the opium alkaloid, thebaine, and may be represented by the following structural formula: 

Oxycodone and Acetaminophen Tablets, USP, contain acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder. The molecular formula for acetaminophen is C 8H 9NO 2 and the molecular weight is 151.16. It may be represented by the following structural formula:
Combining chemoradiation with an antiangiogenic agent has a strong biological rationale, and preclinical studies consistently show an increase in radiosensitization with combined treatment. It is well described that hypoxia or HIF-1 expression is associated with a lower radiation response and progression in solid tumors. Radiation itself induces transient tumor hypoxia, which in turn stimulates VEGF production and VEGFR-2 expression what may also serve as a paracrine proliferative stimulus that promotes out-of-field growth. The combination of radiotherapy with an antiangiogenic agent (e.g. bevacizumab) thus offers the potential to enhance the effect of radiation, and avoid further spread of disease. Furthermore, targeting tumor vasculature improves the delivery of cytotoxic drugs (e.g. capecitabine) leading to increased efficacy of chemoradiation. Combination with cytotoxic drugs could additionally limit treatment-induced hypoxia (Senan and Smit 2007; Mazeron, Anderson et al. 2011).
To evaluate the usefulness of NAC as pre-treatment attempt associated with a culture-guided antibiotic therapy as rescue therapy after multi-attempts antibiotic failure, in the first phase of the study, the effect of NAC on biofilm formation and on its demolition will be tested in vitro by adding NAC in cultured H pylori isolates from a limited number of patients (n10) with an history of at least 4 failed eradicating attempts. Two biopsy samples of gastric mucosa will be obtained during endoscopy for microbiological purpose. Specimens will be used for H pylori culture. In specimens from 5 patients, H pylori will be cultured together with NAC 2 mg, while in the other 5 cases, H pylori culture will be carried out without NAC. In these latter, after the biofilm formation, H pylori isolates will be faced with different doses of NAC (2 mg, 10 mg, and 20 mg) to observe the behavior of biofilm. In the second phase of the study, 40 patients, after at least four unsuccessful H pylori eradication attempts, will be consecutively recruited. During endoscopy, in each patient, at least 4 mucosal biopsies will be obtained from the gastric body. Two of these biopsies will be used for biofilm study at the scanning electron microscopy (SEM). The remaining biopsies will be used for H pylori culture. From culture, the in vitro antibiotic susceptibility testing together with genetic analysis of H pylori isolates will be performed. On the basis of antibiotic susceptibility testing alone, patients will then randomly assigned to receiving two different eradication schedules: Group A, patients receiving NCA 600 mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics against H pylori; group B (control), patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics. Sensitive antibiotics will be always chosen on the basis of the more favorable minimum inhibiting concentration value. all patients will have a diary to record the side effects and symptoms during therapy. Compliance will measured by counting the tablets returned after the 7-day treatment. Patients will take a control C13 urea breath test at least two months after the end of therapy. They will be also invited to repeat endoscopic examination for monitoring biofilm persistence or absence. Finally, results obtained with the two treatment arms will be compared and evaluated also on the light of genetic analyses of H pylori isolates.
Compare rapidity of CNS effects of levetiracetam (LEV) \& brivaracetam (BRV) within same pt-(randomized, two-way crossover, dbl-blind in total 16 pts w/epilepsy. Pt 1: IV infusion over 15 min BRV will also be administered as 15-min.infusion. BRV vs LEV in randomized double blinded, crossover fashion.
Patients will be recruited around the time of their routine obstetrical visits. They will be asked to participate in three visits total. Visit one/enrollment occurs between 16 and 20 weeks of gestation, visit two at 20-24 weeks, and visit three at 24-28 weeks. At each visit, vaginal swabs will be collected. The patient will also be asked to fill out a series of surveys related to stress, anxiety,and depression in pregnancy. Research coordinators will perform chart abstraction after delivery.
Systems and methods for displaying medical or physiologic data are disclosed. The system can receive medical data such as a physiologic trend indicative of worsening of heart failure. The system can generate a graphical representation of the medical data in a two-dimensional or a higher-dimensional coordinate space. The graphical representation can include line segments indicating temporal variation of the medical data. The system can determine a desired range, including lower and upper bounds, for displaying the medical data using signal statistics and a correction factor, and specified number of tickmarks between the desired LB and UB. The desired lower and upper bounds can enhance visual perception of temporal variation of the medical data, and thus to facilitate data interpretation and clinical decision making. A display unit can display the graphical representation of the medical data within the desired lower and upper bounds.
Participants received chemotherapy and pegfilgrastim administered as a single subcutaneous injection dose of 6 mg 24 to 72 hours after chemotherapy. Participants were required to watch a bone pain education DVD on 2 separate visits to the clinic prior to the first administration of pegfilgrastim in cycle 1.
An ERCP with biliary sphincterotomy will be performed. The performance of other techniques (balloon extraction, dilation, placement of biliary prosthesis ...) is at the expense of the endoscopist. After this, transmural drainage of the gallbladder will be performed by placing a LAMS Axios (Boston Scientific) usually 15x10 mm or 10x10 mm to allow direct cholecystoscopy with a conventional gastroscope or transnasal gastroscope. The placement of the drainage will be performed in the same endoscopic act, by means of an Olympus® sectorial echoendoscope, assisted with X-rays, which allows puncturing the vesicle from the gastric antrum or the duodenal bulb to generate a cholecysto-gastrostomy or cholecysto-duodenostomy respectively. After the puncture of the vesicle from the most optimal anatomical point, it will be tutored with guidance and a Hot Axios® PAL will be placed on it to generate the anastomosis between the aforementioned structures.
Program with 8 face to face sessions (115 minutes/session) in groups of 15-18 people. This program was adapted from BA proponents and excludes terms and interventions from Third Generation Therapies.